Zhang Siqi, Tang Fei, Zhou Zhe, Li Linhui, Tang Yang, Fu Kaiwen, Tan Yang, Li Ling
Hunan Key Laboratory of Integrated Chinese and Western Medicine for Prevention and Treatment of Heart and Brain Diseases, Hunan University of Chinese Medicine, Changsha 410208, China.
College of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Int J Mol Sci. 2025 Jul 11;26(14):6666. doi: 10.3390/ijms26146666.
Liver fibrosis remains a critical health concern with limited therapeutic options. Kaempferol (Kae) is a natural flavonoid widely present in natural plants, yet its role in modulating gut-liver axis interactions during fibrosis is unexplored. This study investigates the hepatoprotective effects of Kae on alleviating carbon tetrachloride (CCl)-induced liver fibrosis, and its underlying mechanisms, focusing on oxidative stress, gut microbiota, and short-chain fatty acids (SCFAs), are revealed. A mouse model of hepatic fibrosis was built by the subcutaneous injection of CCl. Meanwhile, Kae was administered by gavage at doses of 25, 50, and 100 mg/kg body weight. Serum biomarkers, liver histopathology, oxidative damage markers, and nuclear factor erythroid 2-related factor 2 (Nrf2)/kelch-like ECH-associated protein 1 (Keap1)/heme oxygenase 1 (HO-1) signaling were analyzed. AML12 hepatocytes were pretreated with Kae or SCFAs (acetate, propionate, butyrate) before HO-induced oxidative injury. The changes in gut microbiota and the levels of SCFAs were assessed via 16S rRNA sequencing and GC-MS, respectively. Kae effectively alleviated the destruction of the liver morphology and tissue structure, reduced the infiltration of inflammatory cells, collagen deposition in the liver, and the expression of fibrotic factors, and downregulated the oxidative stress level in the liver of mice with liver fibrosis by activating the Nrf2/Keap1/HO-1 pathway ( < 0.05 or 0.01). In vitro, Kae significantly mitigated HO-induced cytotoxicity and oxidative damage ( < 0.05 or 0.01). Furthermore, Kae restored gut microbiota diversity, increased beneficial genera (e.g., ), and elevated both intestinal and hepatic SCFA levels ( < 0.01). The discrepant SCFA pretreatment similarly protected AML12 cells by activating Nrf2 signaling ( < 0.05 or 0.01). Our research suggests that Kae could inhibit CCl-induced liver fibrosis by restoring the levels of intestinal metabolite SCFAs to reduce oxidative damage.
肝纤维化仍然是一个严重的健康问题,治疗选择有限。山奈酚(Kae)是一种广泛存在于天然植物中的天然黄酮类化合物,但其在纤维化过程中调节肠-肝轴相互作用的作用尚未得到探索。本研究调查了Kae对减轻四氯化碳(CCl)诱导的肝纤维化的肝保护作用,并揭示了其潜在机制,重点关注氧化应激、肠道微生物群和短链脂肪酸(SCFAs)。通过皮下注射CCl建立肝纤维化小鼠模型。同时,以25、50和100mg/kg体重的剂量通过灌胃给予Kae。分析了血清生物标志物、肝脏组织病理学、氧化损伤标志物和核因子红细胞2相关因子2(Nrf2)/kelch样ECH相关蛋白1(Keap1)/血红素加氧酶1(HO-1)信号通路。在HO诱导的氧化损伤之前,用Kae或SCFAs(乙酸盐、丙酸盐、丁酸盐)预处理AML12肝细胞。分别通过16S rRNA测序和气相色谱-质谱法评估肠道微生物群的变化和SCFAs的水平。Kae通过激活Nrf2/Keap1/HO-1途径有效减轻了肝纤维化小鼠肝脏形态和组织结构的破坏,减少了炎症细胞浸润、肝脏胶原沉积和纤维化因子的表达,并下调了肝脏的氧化应激水平(<0.05或0.01)。在体外,Kae显著减轻了HO诱导的细胞毒性和氧化损伤(<0.05或0.01)。此外,Kae恢复了肠道微生物群多样性,增加了有益菌属(如),并提高了肠道和肝脏的SCFA水平(<0.01)。不同的SCFA预处理同样通过激活Nrf2信号通路保护AML12细胞(<0.05或0.01)。我们的研究表明,Kae可以通过恢复肠道代谢物SCFAs的水平来减少氧化损伤,从而抑制CCl诱导的肝纤维化。